Drug pricing proposals. Pharmacy Benefit Manager reform proposals, clinical trial reforms, 340B. Vaccine safety and access issues, FDA reforms and changes, drug supply and shortage issues. Issues related to TrumpRX.
2026 · 3rd Quarter (July 1 - Sep 30)
MERCK & CO INC
Filed by WILLIAMS AND JENSEN, PLLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- WILLIAMS AND JENSEN, PLLC
- Client
- MERCK & CO INC
- Filing UUID
- c065b286-c8dd-4af7-9d47-74230c4f8be6
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Tax policy impacting health care and pharmaceutical industry; implementation of PL 119-21.
Drug pricing proposals. Pharmacy Benefit Manager reform proposals. ORPHAN CURES Act, Implementation of IRA, and policy changes including the EPIC Act, Medicaid drug rebate program, Issues related to drug pricing in Medicare Parts B and D; Issues related to Most Favored Nation (MFN) drug pricing proposals.
General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Pharmacy Benefit Manager (PBM) policy issues.
Monitor Section 232 investigations, new trade agreements and tariffs, pharmaceutical IP. Issues related to China WRT the BINSA bill.
Issues related to China WRT the BINSA bill.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.